Thermo Fisher Scientific Introduces All-in-One AAV Production System
The Gibco CTS AAV-MAX Helper-Free AAV Production System, a new all-in-one solution from Thermo Fisher Scientific, has been developed to help fulfil clinical and business demands for the affordable and scalable production of adeno-associated virus (AAV)-based gene treatments. It is currently the only product of its kind to be produced following cGMP guidelines in order to support large-scale applications.
The CTS AAV-MAX System, a part of Cell Therapy Systems (CTS) solutions, is created to operate inside the AAV manufacturing workflow, from cell culture and transfection through the creation of AAV viral vectors. Researchers can easily switch from conducting research using the Gibco AAV-MAX Helper Free AAV Production System to employing the CTS AAV-MAX System on a clinical scale. Thermo Fisher’s CTS products are commonly utilised in commercial production to meet the manufacturing requirements of developers of cell and gene therapies. These products are cGMP made, include traceability, and regulatory paperwork.
AAV is used in 82% of viral vector-based gene therapies in the pipeline, and scaled production is critical to accelerate the transition from research to commercialization to bring gene therapies to market faster and at lower costs.1 By delivering high titer AAV production, the system can save manufacturers up to 50% on production costs compared to alternative polyethyleneimine (PEI)-based suspension systems and help reduce plasmid DNA costs by 25%. It features a mammalian-based suspension system comprised of a clonal HEK293 cell line and animal origin-free reagents that support scalable AAV production from shake flask to bioreactor scale.